Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02908425 · ClinicalTrials.gov registry record · NA
Cholesterol and Statin in Healthy Adults
A NA study of Elevated HMB Excretion, sponsored by Texas A&M University.
- Completed
- Registry status
- NA
- Development phase
- 13
- Enrollment target
- 1
- Study location
NCT02908425 is a NA study of Elevated HMB Excretion that has completed, run by Texas A&M University. The registered enrollment target is 13 participants. The trial reports 1 study location across 1 state.
The verdict
NCT02908425, a NA study of Elevated HMB Excretion, has completed, sponsored by Texas A&M University.
- COMPLETED
- Registry status
- NA
- Development phase
- 13 participants
- Enrollment target
- 1
- Study location
Study Summary
Statins are a class of drugs that are the most commonly prescribed medications in developing countries. Statins act on the enzyme HMG-CoA reductase to inhibit its conversion to mevalonate, a precursor for cholesterol synthesis. Subsequently statins are prescribed to patients with relatively high blood cholesterol levels. However, taking statins does not come without side effects. Most notably, the effects of statins on muscle wasting have been studied extensively. This includes up-regulation of the ubiquitin proteasome system, muscle cell damage and rhabdomyolysis, elevated creatine kinase, and mitochondrial dysfunction. Due to the negative side effects of statin therapy, additional therapies are warranted to help offset the effects on muscle wasting. Loss of muscle mass is a significant concern as it is associated with a reduction in muscle strength and power (Ferrando et al., 1996; Creditor, 1993). This condition is observed in aging, disease states, and long periods of unloading such as hospital admission and can lead to disability, increased falls, loss of independence, and mortality. Subsequently, there is a critical need to develop interventions to counteract this loss of muscle mass and strength. Exercise is one such intervention, however, in some cases may not be a feasible option. For instance, exercise has been demonstrated to exacerbate the muscle side of effects of statins. Subjects complain of increased muscle soreness and have elevated creatine kinase levels and they also do not want to take statins anymore (Kearns et al., 2008; Parker et al., 2012; Sinzinger et al., 2004). Because of this limitation, there is a critical need to develop other interventions that can prevent the loss of muscle mass during statin use.
Conditions Studied
Interventions
- OTHER Statin user
Study Locations (1)
Texas
- Texas A&M University CTRAL - College Station
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2016-07-08 |
| Est. Completion | 2017-03-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02908425
The ClinicalTrials.gov registry entry for NCT02908425 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Texas A&M University, which has 95 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Elevated HMB Excretion appearing as the primary indexed condition, and to 1 intervention - of which Statin user is the first listed.
NCT02908425 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT02908425 about?
NCT02908425 is a clinical study titled "Cholesterol and Statin in Healthy Adults". Statins are a class of drugs that are the most commonly prescribed medications in developing countries. Statins act on the enzyme HMG-CoA reductase to inhibit its conversion to mevalonate, a precursor for cholesterol synthesis. Subsequently statins are prescribed to patients with relatively high blo...
What is the current status of trial NCT02908425?
This trial is currently completed. It is a NA study. The enrollment target is 13 participants. The study started on 2016-07-08. Estimated completion is 2017-03-01.
What conditions does trial NCT02908425 study?
This clinical trial studies the following conditions: Elevated HMB Excretion.
What interventions are being tested in trial NCT02908425?
The interventions under investigation include: Statin user (OTHER).
Who is sponsoring clinical trial NCT02908425?
This trial is sponsored by Texas A&M University, which has 95 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02908425 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.